Aditya Bardia Selected Research

Cyclin-Dependent Kinase 4

10/2022	Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
1/2022	Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities.
1/2022	AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2- advanced breast cancer.
1/2021	Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1).
11/2020	POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer.
1/2020	Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.
1/2020	Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7).
12/2019	Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial.
1/2019	Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer.
1/2019	Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Aditya Bardia Research Topics

Disease

91	Breast Neoplasms (Breast Cancer) 10/2022 - 05/2006
73	Neoplasms (Cancer) 01/2022 - 03/2007
22	Triple Negative Breast Neoplasms 09/2022 - 07/2017
9	Neoplasm Metastasis (Metastasis) 09/2022 - 08/2014
9	Circulating Neoplastic Cells 07/2021 - 04/2013
9	Disease Progression 03/2021 - 02/2013
7	Pathologic Complete Response 10/2021 - 12/2013
7	Neutropenia 01/2021 - 01/2017
4	Nausea 10/2022 - 01/2008
3	Brain Neoplasms (Brain Tumor) 06/2022 - 01/2021
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 08/2017
3	Melanoma (Melanoma, Malignant) 01/2021 - 03/2007
3	Ovarian Neoplasms (Ovarian Cancer) 01/2020 - 02/2008
3	Hot Flashes 05/2009 - 07/2006
2	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 06/2014
2	Lung Neoplasms (Lung Cancer) 01/2022 - 12/2017
2	Infections 01/2021 - 01/2019
2	Anemia 01/2021 - 08/2018
2	Wounds and Injuries (Trauma) 01/2019 - 01/2018
2	Prostatic Neoplasms (Prostate Cancer) 08/2018 - 08/2009
2	Fatigue 01/2018 - 01/2017
2	Retinoblastoma (Glioblastoma, Retinal) 01/2017 - 01/2016
2	Carcinogenesis 01/2016 - 08/2009
2	Cardiovascular Diseases (Cardiovascular Disease) 09/2012 - 02/2012
2	Colonic Neoplasms (Colon Cancer) 09/2011 - 02/2010
2	Vomiting 07/2011 - 01/2008
2	Rickets (Rachitis) 04/2005 - 01/2005
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022

Drug/Important Bio-Agent (IBA)

37	Hormones (Hormone)IBA 09/2022 - 07/2006
18	Estrogen ReceptorsIBA 10/2022 - 12/2006
18	sacituzumab govitecanIBA 09/2022 - 07/2017
17	Biomarkers (Surrogate Marker)IBA 01/2022 - 08/2009
16	ribociclibIBA 03/2022 - 01/2016
14	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 04/2017
13	Cyclin-Dependent Kinase 4IBA 10/2022 - 01/2017
9	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2022 - 01/2016
9	Pharmaceutical PreparationsIBA 01/2022 - 04/2007
9	Aromatase InhibitorsIBA 01/2022 - 02/2012
8	human ERBB2 proteinIBA 10/2022 - 01/2014
7	ErbB Receptors (EGF Receptor)IBA 10/2022 - 01/2012
7	palbociclibIBA 01/2022 - 01/2016
7	Cell-Free Nucleic AcidsIBA 01/2022 - 10/2018
6	RNA (Ribonucleic Acid)IBA 01/2021 - 08/2014
6	Progesterone Receptors (Progesterone Receptor)IBA 01/2021 - 12/2006
6	Estrogens (Estrogen)FDA Link 01/2021 - 01/2008
5	Circulating Tumor DNAIBA 01/2022 - 10/2018
5	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2020
5	Letrozole (Femara)FDA LinkGeneric 01/2022 - 01/2018
5	pertuzumabIBA 10/2021 - 12/2013
5	AntigensIBA 10/2021 - 12/2017
5	Everolimus FDA Link 01/2021 - 01/2017
5	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 04/2020 - 06/2007
4	Fulvestrant (Faslodex)FDA Link 01/2022 - 10/2019
4	Ado-Trastuzumab EmtansineIBA 10/2021 - 12/2017
4	Irinotecan (Camptosar)FDA LinkGeneric 10/2021 - 10/2017
4	Trastuzumab (Herceptin)FDA Link 08/2021 - 01/2012
4	abemaciclibIBA 03/2021 - 01/2016
3	elacestrantIBA 10/2022 - 10/2019
3	taxaneIBA 12/2021 - 08/2021
3	AnthracyclinesIBA 12/2021 - 01/2019
3	Monoclonal AntibodiesIBA 10/2021 - 01/2014
3	Proteins (Proteins, Gene)FDA Link 10/2021 - 01/2019
3	DNA (Deoxyribonucleic Acid)IBA 07/2021 - 01/2016
3	exemestane (Aromasin)FDA Link 01/2021 - 08/2019
3	Paclitaxel (Taxol)FDA LinkGeneric 09/2018 - 01/2016
2	AntibodiesIBA 01/2022 - 01/2020
2	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2022 - 01/2020
2	trastuzumab deruxtecanIBA 01/2022 - 01/2020
2	Capecitabine (Xeloda)FDA Link 12/2021 - 01/2021
2	Taxoids (Taxanes)IBA 10/2021 - 01/2019
2	Phosphotransferases (Kinase)IBA 10/2021 - 01/2018
2	Surface Antigens (Surface Antigen)IBA 10/2021 - 01/2021
2	LigandsIBA 07/2021 - 01/2016
2	RAD1901IBA 01/2021 - 10/2019
2	Aromatase (CYP19)IBA 01/2021 - 02/2011
2	CalciumIBA 04/2020 - 04/2005
2	Neoplasm Antigens (Tumor Antigens)IBA 01/2020 - 04/2013
2	EpitopesIBA 01/2020 - 04/2013
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2020 - 01/2020
2	Phenobarbital (Luminal)FDA Link 01/2019 - 11/2015
2	Androgen Receptors (Androgen Receptor)IBA 08/2018 - 01/2018
2	Hemoglobins (Hemoglobin)IBA 02/2017 - 01/2013
2	Cyclin DIBA 01/2017 - 01/2016
2	salicylhydroxamic acid (SHAM)IBA 02/2014 - 12/2006
2	Fluorouracil (Carac)FDA LinkGeneric 09/2011 - 02/2010
2	AntiemeticsIBA 07/2011 - 01/2008
2	Progesterone FDA LinkGeneric 02/2011 - 02/2008
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 02/2011 - 06/2007
2	AntioxidantsIBA 08/2009 - 01/2008
2	Vitamin D FDA LinkGeneric 04/2005 - 01/2005
1	Ad26COVS1IBA 01/2022

Therapy/Procedure

80	Therapeutics 10/2022 - 01/2005
18	Drug Therapy (Chemotherapy) 10/2022 - 04/2007
10	Neoadjuvant Therapy 01/2020 - 01/2013
6	Immunotherapy 01/2022 - 01/2020
5	Precision Medicine 01/2021 - 01/2014
4	Adjuvant Chemotherapy 06/2022 - 05/2006
2	Lymph Node Excision (Lymph Node Dissection) 06/2019 - 04/2007
2	Aftercare (After-Treatment) 01/2018 - 08/2017
2	Chemoprevention 01/2016 - 08/2009